Skip to Main Content

Paper Details

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
Clin Gastroenterol Hepatol
23
2022
TNF, Tumor Necrosis Factor, Ulcerative Colitis, Vedolizumab, infliximab, patients, tumor necrosis factor, ulcerative colitis, vedolizumab
Author NameAffiliation
Dana J LukinMontefiore Medical Center
Ronghui XuUniversity of California
Brigid S BolandUniversity of California
Brigid S BolandUniversity of California
Siddharth SinghUniversity of California
Robert HirtenIcahn School of Medicine at Mount Sinai
Eugenia ShmidtUniversity of Minnesota
Vipul JairathUniversity of Western Ontario
David HudesmanNew York University
Arun SwaminathLenox Hill Hospital
Sunanda V KaneMayo Clinic
Edward V LoftusMayo Clinic
Bruce E SandsIcahn School of Medicine at Mount Sinai
Jean-Frederic ColombelIcahn School of Medicine at Mount Sinai
Corey A SiegelDartmouth-Hitchcock Medical Center
William J SandbornUniversity of California
Parambir S DulaiUniversity of California
  • 1 - 17

Datasets

Release 1.2